NDAORALCAPSULE, DELAYED RELEASE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
DORYX (doxycycline hyclate) by Pfizer is tetracycline-class antimicrobial drug [ see ]. First approved in 1985.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORYX is a delayed-release oral capsule formulation of doxycycline hyclate, a tetracycline-class antimicrobial drug approved in 1985. It is used to treat bacterial infections across multiple therapeutic areas. The drug works by inhibiting bacterial protein synthesis, making it a broad-spectrum antibiotic.
$0.018BPart D
LOE ApproachingThis mature product with approaching loss of exclusivity signals consolidation of brand teams and shift toward lifecycle extension or managed decline strategies.
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Started May 2010
164 enrolled
Mucositis
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Started Aug 2008
459 enrolled
Severe Acne Vulgaris
Career Relevance
Working on DORYX offers limited career growth given its mature, generic-threatened lifecycle stage and minimal linked job openings (0 detected). Roles available are primarily in brand defense, managed care negotiations, and portfolio rationalization rather than expansion.
Brand Manager
Worked on DORYX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.